Zobrazeno 1 - 10
of 110
pro vyhledávání: '"Liying Du"'
Publikováno v:
Therapeutic Drug Monitoring; Jun2024, Vol. 46 Issue 3, p344-350, 7p
Autor:
Liying Du, Liman Huo, Juan Hou, Xiajin Zhou, Mingfeng Liu, Teng Guo, Wei Wang, Huihui Chen, Xinran Chen
Publikováno v:
Biopharmaceutics & Drug Disposition. 44:175-182
Publikováno v:
Nature Medicine.
Publikováno v:
Diabetes, Obesity & Metabolism
Aim To compare the efficacy and safety of LY2963016 insulin glargine (LY IGlar) with insulin glargine (Lantus; IGlar) combined with oral antihyperglycaemic medications (OAMs) in insulin‐naive Chinese patients with type 2 diabetes (T2D). Materials a
Autor:
Huijuan Yuan, Jiankun Zhu, Linong Ji, Lulu Chen, Tianshu Zeng, Jiangong Ren, Yuanyuan Li, Liying Du, Jianing Hou
Publikováno v:
Diabetes Therapy
Introduction According to Chinese guidelines, basal insulin (BI) or premixed insulins are recommended insulin starters following the failure of oral antihyperglycemic medication (OAM) in Chinese patients with type 2 diabetes (T2D). This pragmatic stu
Publikováno v:
Annals of clinical biochemistry. 59(4)
Background Vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib are five commonly used drugs which are all recommended to therapeutic drug monitoring in clinical settings. However, the blood concentration monitoring of these drugs and th
Publikováno v:
Diabetes, obesitymetabolism. 24(6)
To evaluate the immunogenicity of LY2963016 insulin glargine (LY IGlar) versus originator insulin glargine (IGlar [Lantus®]) in Chinese patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM).ABES and ABET were prospective, randomized, active
Publikováno v:
Metallurgical & Mining Industry. 2015, Issue 7, p282-290. 9p.